- Home
- LOAN vs NRXP Comparison
LOAN vs NRXP Comparison
Compare LOAN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOAN
- NRXP
- Stock Information
- Founded
- LOAN 1989
- NRXP 2015
- Country
- LOAN United States
- NRXP United States
- Employees
- LOAN N/A
- NRXP N/A
- Industry
- LOAN Real Estate Investment Trusts
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- LOAN Real Estate
- NRXP Health Care
- Exchange
- LOAN Nasdaq
- NRXP Nasdaq
- Market Cap
- LOAN 61.5M
- NRXP 58.5M
- IPO Year
- LOAN 1999
- NRXP N/A
- Fundamental
- Price
- LOAN $5.36
- NRXP $2.80
- Analyst Decision
- LOAN
- NRXP Strong Buy
- Analyst Count
- LOAN 0
- NRXP 5
- Target Price
- LOAN N/A
- NRXP $31.40
- AVG Volume (30 Days)
- LOAN 20.4K
- NRXP 533.2K
- Earning Date
- LOAN 10-22-2025
- NRXP 08-18-2025
- Dividend Yield
- LOAN 8.58%
- NRXP N/A
- EPS Growth
- LOAN N/A
- NRXP N/A
- EPS
- LOAN 0.48
- NRXP N/A
- Revenue
- LOAN $7,300,469.00
- NRXP N/A
- Revenue This Year
- LOAN N/A
- NRXP N/A
- Revenue Next Year
- LOAN $4.47
- NRXP $231.16
- P/E Ratio
- LOAN $11.17
- NRXP N/A
- Revenue Growth
- LOAN N/A
- NRXP N/A
- 52 Week Low
- LOAN $4.74
- NRXP $1.10
- 52 Week High
- LOAN $6.05
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- LOAN 47.86
- NRXP 51.92
- Support Level
- LOAN $5.30
- NRXP $2.26
- Resistance Level
- LOAN $5.44
- NRXP $3.19
- Average True Range (ATR)
- LOAN 0.11
- NRXP 0.23
- MACD
- LOAN 0.00
- NRXP 0.05
- Stochastic Oscillator
- LOAN 71.43
- NRXP 58.13
About LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.